Important note: Information in this article was accurate in October 2006. The state of the art may have changed since the publication date.
Introduction
HIV Treat Bull - 2006 October;7(10):
This annual Workshop is the most important meeting for researchers, clinicians and advocates who focus on metabolic complications relating to management of HIV-positive patients.
While many studies reaffirmed the role of some ARVs in risk factors associated with lipodystrophy, cardiovascular disease and diabetes, there was further evidence on managing this risk by treatment choice. While lipoatrophy is now firmly linked to use of thymidine analogues and some degree of fat reversal occurs when switching to alternative drugs, notably tenofovir or abacavir, the mechanism to reverse fat accumulation is less clear.
Research into lipodystrophy over the last few years has increasingly focused on understanding adipogenesis as a dynamic process, and on the role of two major proteins produced by adipocytes: leptin and adiponectin, which act as hormones in their effect on different organs. At this years workshop, the role of inflammation by macrophage and lymphocyte activity in adipose tissue was also shown to be an increasingly important factor.
Although an interesting study suggested that leptin may be a useful treatment for reducing central fat accumulation, this research has been slow and leptin isn’t a clinical option at the moment. Prevention, through choice of initial treatment, switching treatment when necessary and lifestyle modification, was still stressed as the take-home message.
Clinical discussions included the role of the metabolic syndrome, and the high incidence of risk factors for insulin resistance and progression to type-2 diabetes in patients with HIV - and the degree to which this risk is underestimated.
Reports in this issue include:
For the first time, the organisers of the meeting have produced webcasts of many of the key presentations and discussions. This is a very positive and important step towards making medical research presented at the workshop available to a wider audience. Abstracts from the meeting together with webcasts of oral sessions and some slide presentations are posted on the conference website:
2006-10-10
IB060710-03
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.